Anticholinergic Burden Tied to Adverse Effects in Middle Age
Identification of at-risk populations varies by scale used, which could impact clinical practice
Overactive Bladder (OAB)
OVERACTIVE BLADDER (OAB)
Vibegron Under Review for Overactive Bladder Treatment
The FDA has accepted for review the New Drug Application for vibegron (Urovant Sciences) for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Try Behavioral Therapy First When Treating Overactive Bladder in Men
New study results reinforce OAB guidelines recommending behavioral therapy as first-line treatment.
NDA Submitted for Vibegron for Overactive Bladder Treatment
Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The NDA submission includes data from an extensive clinical development program involving over 4000 patients with…
Nocturia Etiology in Men Does Not Differ By Race
Similar proportions of black and white men had each type of nocturia.
Dementia Tied to Anticholinergic Use
In a prospective study, the odds of dementia increased nearly 50% with daily use of anticholinergics for 3 years at the minimum effective dose recommended for older adults.
OTC Urethral Support Device Now Available to Treat Stress Urinary Incontinence
An over-the-counter device to treat stress urinary incontinence (SUI) in women has been made available by Rinovum Women’s Health.
AUA Updates Overactive Bladder Guideline
Updated OAB guideline now says clinicians may consider combination therapy with an antimuscarinic and beta3-andrenoceptor agonist for patients refractory to monotherapy with either of those medications.
Solabegron Meets Primary Endpoint in Overactive Bladder Study
Velicept Therapeutics announced that solabegron met the primary endpoint in the phase 2b VEL-2002 study that evaluated patients with overactive bladder (OAB).
Vibegron Cuts Daily Urge Urinary Incontinence Episodes, Micturitions in OAB Study
Urovant Sciences announced topline data from the phase 3 EMPOWUR trial which evaluated vibegron in adult patients with symptoms of overactive bladder.
Want to read more?
Please login or register first to view this content.
Next post in Overactive Bladder (OAB)
